Feb 15, 2023 / 10:00PM GMT
Joseph Schwartz - SVB Securities - Moderator
Hello. Welcome to this fireside chat with Design Therapeutics. I'm pleased to be joined by Joao Siffert, Chief Executive Officer. Thanks for joining us today.
Joao Siffert - Design Therapeutics, Inc. - CEO
Thank you. Yeah, thanks for having us.
Joseph Schwartz - SVB Securities - Moderator
So it's an exciting time for the company. Wondering if you can start us off with a brief overview of your GeneTAC platform technology, the key pipeline programs you're pursuing, and what catalysts they'll have over the next -- the rest of the year.
Joao Siffert - Design Therapeutics, Inc. - CEO
Okay. Thanks, Joe. So we're a pioneering in a very exciting new platform of small molecules that we call Gene Targeted Chimeras or GeneTAC molecules for short. And these are molecules that are capable of targeting a specific gene and harness the person's own cell mechanisms to either dial up or to dial down gene expression without any need for irreversible
Design Therapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 16, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers